<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002090'>Pneumonia</z:hpo> caused by Stenotrophomonas maltophilia is rare, but can be lethal in severely immunocompromised patients </plain></SENT>
<SENT sid="1" pm="."><plain>However, its clinical course remains unclear </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Patients with <z:hpo ids='HP_0002090'>pneumonia</z:hpo> caused by S. maltophilia in Toranomon Hospital (890 beds, Tokyo, Japan) were reviewed retrospectively between April 2006 and March 2010 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: During the study period, 10 cases of S. maltophilia <z:hpo ids='HP_0002090'>pneumonia</z:hpo> were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients had <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, 2 had <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and 1 had malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients developed symptoms after allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients received first cord blood transplantation (CBT), 4 patients received second CBT, and 1 patient received first peripheral blood stem cell transplantation (PBSCT) </plain></SENT>
<SENT sid="7" pm="."><plain>The overall incidence of S. maltophilia <z:hpo ids='HP_0002090'>pneumonia</z:hpo> among 508 patients who received HSCT during the period was 2.0% </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence was 0% (0/95) in patients after bone marrow transplantation, 0.8% (1/133) after PBSCT, and 3.2% (9/279) after CBT </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002090'>Pneumonia</z:hpo> developed a median of 13.5 days (range, 6-40) after transplantation </plain></SENT>
<SENT sid="10" pm="."><plain>At <z:hpo ids='HP_0003674'>onset</z:hpo>, the median white blood cell count was 10/μL (range, 10-1900), and the median neutrophil count was 0/μL (range, 0-1720) </plain></SENT>
<SENT sid="11" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, S. maltophilia <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> developed with bloody sputum or <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The 28-day mortality rate was 100%; the median survival after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was 2 days (range, 1-10) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Hemorrhagic S. maltophilia <z:hpo ids='HP_0002090'>pneumonia</z:hpo> rapidly progresses and is fatal in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Attention should be particularly paid to the neutropenic phase early after HSCT or prolonged <z:hpo ids='HP_0001875'>neutropenia</z:hpo> due to engraftment failure </plain></SENT>
<SENT sid="15" pm="."><plain>A prompt <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi>-based multidrug combination regimen should be considered to rescue suspected cases of S. maltophilia <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in these severely immunosuppressed patients </plain></SENT>
</text></document>